Answers are grounded in this paper and cite their sources.
The development of novel anticancer agents remains a key focus in medicinal chemistry. We hypothesized that benzamide substitution of the 1,8-naphthyridine scaffold would enhance anticancer activity. In this study, we report a rapid, efficient, and environmentally benign green synthetic approach for the construction of a new series of N-(5,7-dimethyl-1,8-naphthyridin-2-yl)benzamide derivatives (5a-h). The synthesized compounds were characterized using standard spectroscopic techniques. All compounds were evaluated for their in vitro anticancer activity against three human cancer cell lines: MCF-7, A549, and Colo-205. The results revealed that the tested compounds exhibited significant anticancer activity. Among them, N-(5,7-dimethyl-1,8-naphthyridin-2-yl)-2-nitrobenzamide (5e) and 2-chloro-N-(5,7-dimethyl-1,8-naphthyridin-2-yl)benzamide (5c) showed the most potent activity, with IC50 values of 6.06 ± 0.14 μM (MCF-7), 8.36 ± 0.36 μM (A549), and 12.27 ± 0.73 μM (Colo-205) for compound 5e, and 8.06 ± 0.29 μM (MCF-7), 10.72 ± 0.49 μM (A549), and 15.39 ± 0.43 μM (Colo-205) for compound 5c, compared with the standard drug.
No takes yet. Share an insight, caveat, or question.
Venkatesh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: